DPYD Antibody (A-5): sc-376712

DPYD Antibody (A-5) is a mouse monoclonal IgG2a kappa light chain antibody that detects DPYD protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). DPYD (A-5) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Dihydropyrimidine dehydrogenase (DPYD) plays a crucial role in the metabolism of pyrimidines, catalyzing the first rate-limiting step in the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine. DPYD deficiency can lead to the accumulation of uracil and thymine, potentially contributing to neurological disorders and posing significant risks for cancer patients undergoing treatment with certain pyrimidine analogs. DPYD is integral to the metabolic pathway of the anticancer drug 5-fluorouracil (5-FU), influencing both efficacy and potential toxicity. Variations in DPYD expression can occur due to transcriptional changes, such as hypermethylation of the DPYD promoter, which can downregulate enzyme expression. Individuals with deficient DPYD alleles may experience severe toxic reactions following 5-FU treatment, highlighting the importance of understanding DPYD′s function in clinical settings.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DPYD Antibody (A-5) References:

1. Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography.  |  Fischer, J., et al. 2003. Genet Test. 7: 97-105. PMID: 12885330
2. Head imaging abnormalities in dihydropyrimidine dehydrogenase deficiency.  |  Enns, GM., et al. 2004. J Inherit Metab Dis. 27: 513-22. PMID: 15303009
3. Dihydropyrimidine dehydrogenase deficiency presenting at birth.  |  Al-Sanna'a, NA., et al. 2005. J Inherit Metab Dis. 28: 793-6. PMID: 16151913
4. Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency.  |  Yu, J., et al. 2006. Clin Cancer Res. 12: 3864; author reply 3864. PMID: 16778115
5. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.  |  Offer, SM., et al. 2014. Cancer Res. 74: 2545-54. PMID: 24648345
6. Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells.  |  Tuchman, M., et al. 1989. Enzyme. 42: 15-24. PMID: 2528450
7. DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation.  |  Wigle, TJ., et al. 2023. Curr Oncol. 30: 663-672. PMID: 36661700
8. Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.  |  Hertz, DL., et al. 2023. Clin Pharmacol Ther. 114: 768-779. PMID: 37350752
9. The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer.  |  Kato, H., et al. 2024. Cancer Med. 13: e70124. PMID: 39158384
10. [Puerperal psychoses (author's transl)].  |  Gödtel, R. 1978. Geburtshilfe Frauenheilkd. 38: 304-16. PMID: 648855
11. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects.  |  van Gennip, AH., et al. 1997. J Inherit Metab Dis. 20: 203-13. PMID: 9211193
12. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity.  |  Johnson, MR., et al. 1997. J Chromatogr B Biomed Sci Appl. 696: 183-91. PMID: 9323539

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-DPYD Antibody (A-5) has 3 citations in a variety of scientific publications.

Primary antibodies like Anti-DPYD Antibody (A-5) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

DPYD Antibody (A-5) Specifications

Alternate Product Name: DPYD

Product Clone Name: A-5

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 957-989

Epitope Target: DPYD

Epitope Species: human

Product Reactivity/Detection: DPYD

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 3 citations in various scientific publications

Available Conjugates/Forms for DPYD Antibody (A-5): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin